Fertilitas Study

By RRM Academy Reviewed by Dr. Naomi Whittaker, MD, Board-Certified OBGYN, MIGS, NFPMC, FCI Updated May 7, 2026

One of the largest single-center NaProTECHNOLOGY cohort studies to date, demonstrating a take-home baby (THB) rate of 35.3% overall, rising to 62.1% among patients who remained with the program for the full duration of treatment. The study confirmed NaPro as associated with a notably high THB rate even in patients with unfavorable prognostic factors such as advanced maternal age, prolonged infertility duration, and prior failed ART attempts. Conditions associated with higher THB rates included recurrent pregnancy loss, hormonal/functional disorders, endometriosis, and male factor infertility.¹³¹⁴

Sources

4 key findings on infertility from the largest NaPro study to date. . Natural Womanhood
NaProTechnology for infertility: take-home baby rate and clinical outcomes in a 5-year single-center cohort. . PubMed

This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.